RISPERIDONE STUDY RESULTS PRESENTED AT CONFERENCE
Most older patients with depression who have not responded to other treatments
appear to benefit from augmentation of citalopram (Celexa) with risperidone
(Risperdal), according to findings presented at the recent 18th Congress of
the European College of Neuropsychopharmacology, held in Amsterdam, the Netherlands.
The study's investigators were interested in whether risperidone augmentation
of citalopram would be effective in older patients with chronic medical conditions,
because such patients often do not respond to antidepressant therapies. The
researchers evaluated 101 patients who were at least 55 years old and had major
depressive disorder, and had not achieved a benefit from at least one trial
of an antidepressant in the current depressive episode.
In the open-label phase, the patients received daily doses of citalopram monotherapy
for four to six weeks to confirm the lack of a response, defined as less than
50 percent reduction in Hamilton Rating for Depression scale (HAM-D) scores.
A full nonresponse was defined as less than 25 percent reduction in HAM-D scores
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May